Welcome to our dedicated page for 22Nd Century news (Ticker: XXII), a resource for investors and traders seeking the latest updates and insights on 22Nd Century stock.
News for 22nd Century Group, Inc. (Nasdaq: XXII) centers on its role in tobacco harm reduction, regulatory developments, capital structure actions and the commercialization of its VLN® reduced nicotine cigarette platform. Company announcements frequently highlight progress in expanding VLN® and partner VLN® distribution across additional U.S. states and retail chains, including launches with major convenience store operators and authorizations in a large majority of states.
Investors following XXII news will see updates on VLN® regulatory milestones, such as the original FDA Modified Risk Tobacco Product authorization, the filing of the VLN® MRTP renewal application, and the company’s public support for the FDA’s proposed Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products. Releases also discuss clinical research findings related to very low nicotine content cigarettes, including reductions in daily cigarette consumption and increased quit attempts among smokers using 95% reduced nicotine VLN® products.
Another recurring theme in 22nd Century’s news is financial and corporate developments. The company reports on balance sheet changes such as repayment and termination of senior secured debt, settlement of insurance claims related to prior facility incidents, and the use of non-dilutive cash proceeds as growth capital. News items also cover equity and preferred stock financings, at-the-market offering arrangements, and proposals for reverse stock splits and other shareholder approvals under Nasdaq Listing Rules.
In addition, XXII news includes corporate governance and investor relations events, such as participation in investor conferences, quarterly earnings webcasts, and shareholder letters reviewing strategic progress. For readers tracking the intersection of tobacco regulation, reduced nicotine technology and public company capital markets activity, the XXII news feed provides ongoing context on how 22nd Century is executing its harm reduction-focused strategy.
22nd Century Group (Nasdaq: XXII) will release its third quarter 2022 financial results on November 8, 2022, at 6:00 a.m. ET. A conference call will follow at 10:00 a.m. ET, featuring CEO James A. Mish, President John Miller, and CFO Hugh Kinsman. They will discuss company updates and the financial results. Investors can participate in a Q&A session through a webcast. The live event will be available on 22nd Century's Investor Relations website, along with an archived replay.
22nd Century Group, Inc. (XXII) announces the expansion of its VLN® reduced nicotine cigarettes into Utah, Arizona, and New Mexico, following the Colorado launch. The company aims to tap into a massive market, emphasizing that every 1% of the U.S. market correlates to approximately $800 million in retail sales. With favorable MRTP excise tax programs in these states, 22nd Century plans to utilize established partners for efficient distribution. VLN® products are designed to help adult smokers reduce their nicotine intake, with previous pilot programs demonstrating success in consumer recommendations.
22nd Century Group, Inc. (Nasdaq: XXII) has announced that CEO James A. Mish will present at the LD Micro Main Event Investor Conference in Los Angeles on October 26, 2022, at 11:00 a.m. PT. The event is highly anticipated, with limited space for investor meetings due to demand. Institutional investors can arrange meetings through LD Micro representatives or by contacting the investor relations team. A live and archived webcast of the presentation will be available on the company's Investor Relations website shortly after the event.
22nd Century Group (Nasdaq: XXII) announced that CEO James A. Mish will present at the 7th Annual Dawson James Small Cap Growth Conference on October 12, 2022, in Jupiter, Florida. The company's presentation is scheduled for 10:30 AM ET. Interested institutional investors can request meetings with management through their representatives or by contacting the investor relations team at investorrelations@xxiicentury.com. 22nd Century Group specializes in agricultural biotechnology, focusing on reduced nicotine tobacco, hemp, and cannabis technologies.
22nd Century Group has launched VLN® cigarettes in Colorado, the first FDA-approved Modified Risk Tobacco Product, featuring 95% less nicotine than regular cigarettes. This initiative aims to help smokers reduce consumption and quit smoking. VLN® King and Menthol King are now available at Smoker Friendly locations and will soon be in Circle K stores. Clinical trials show switching to VLN® can reduce cigarettes per day by 50% after 20 weeks. The rollout aligns with public health goals and aims to reduce smoking-related deaths, particularly among Colorado's adult smokers.
22nd Century Group (XXII) has partnered with Creager Mercantile to enhance the distribution of its VLN® reduced nicotine content cigarettes across Colorado. This collaboration aims to boost availability in over 1,000 retail locations, including specialty shops and gas stations. VLN® cigarettes contain about 95% less nicotine than standard cigarettes, promoting a non-addictive alternative. The effort follows a successful pilot program in Chicago, establishing a channel for wider retail presence. This partnership represents a strategic move to tap into Colorado's retail market, with plans for further expansion nationwide.
22nd Century Group (Nasdaq: XXII) announced a partnership with Eagle Rock Distributing to launch its VLN® reduced nicotine cigarettes across Colorado starting September 2022. This collaboration aims to distribute VLN® to thousands of locations, including regional and national chains and independent retailers. VLN® cigarettes contain approximately 95% less nicotine, addressing health concerns associated with conventional smoking. The partnership follows a successful pilot program in Chicago, which showed high customer recommendation rates for VLN®. This initiative is aligned with the FDA's proposed nicotine cap to reduce smoking.
22nd Century Group (Nasdaq: XXII) aligns with the FDA and the Biden Administration's initiative to reduce nicotine content in cigarettes, aiming to help smokers cut down. Their VLN® reduced nicotine content cigarettes are designed to aid smokers in reducing their nicotine intake, with plans for expanded sales in Chicago following successful pilot results. The FDA's proposed actions could significantly impact public health, potentially helping over 5 million people quit smoking. These initiatives address the high addiction rates linked to nicotine and the associated health risks, including cancer.
22nd Century Group, Inc. (Nasdaq: XXII) announced the appointment of Lucie S. Salhany to its Board of Directors on September 12, 2022. Salhany, a renowned media executive with a history of successful product launches, will enhance the company's focus on tobacco harm reduction and its hemp/cannabis initiatives. Her experience includes being the first woman chair of a major broadcast network, and she will serve on the Corporate Governance and Finance committees. Board Chair Nora B. Sullivan and CEO James A. Mish expressed confidence in her ability to elevate the company's market profile.
22nd Century Group (Nasdaq: XXII) announced significant management changes aimed at accelerating growth in its reduced nicotine content tobacco business. Michael Zercher, President and COO, will depart by September 30, 2022, while John Miller will take over the tobacco-related duties. CEO James A. Mish will also assume the title of Corporate President. The company reported successful pilot results for its VLN® reduced nicotine tobacco product, paving the way for expanded sales and market rollouts across the U.S. This strategic shift is designed to enhance coordination for upcoming product launches.